UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 15, 2006


                                 REMEDENT, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)


           Nevada                         001-15975               86-0837251
           -------                        ---------               ----------
(State or other jurisdiction of    (Commission File Number)    (I.R.S. Employer
         incorporation                                       Identification No.)
       or organization)

                           Xavier de Cocklaan 42, 9831
                                 Deurle, Belgium
                                 ---------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                011-329-321-7080
                                ----------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

     On February 15, 2006,  Remedent NV, a wholly-owned  subsidiary of Remedent,
Inc. (the "Company") entered into an Agreement with Chefaro Pharma Italia S.R.L,
a corporation organized under the laws of Italy ("Chefaro Italia").  Pursuant to
the Agreement, commencing on March 1, 2006, Chefaro Italia will be the Company's
sole and exclusive  distributor of the iWhite(R) products ("Products") in Italy,
Vatican City, and Republic of San Marino  ("Territory").  The Agreement requires
Chefaro Italia to order minimum  quantities of the Products in accordance to the
terms of the  Agreement.  In the event  that  Chefaro  Italia  fails to sell the
minimum  quantities of the Products within any given year, the Company will have
a right to terminate the Agreement upon one (1) month prior written notice.

     The term of the  Agreement is for an initial  three (3) years (the "Initial
Term"), unless terminated by either party under the Agreement.  After the end of
the Initial Term,  the Agreement will  automatically  be extended for successive
two (2) year terms  ("Additional  Term")  unless the  Agreement is terminated by
written notice at least six (6) months before the expiration of the Initial Term
or the respective  Additional  Term. The Agreement grants Chefaro Italia a first
of first refusal to market,  sell and distribute other product(s) of the Company
on terms  mutually  agreeable  between the  partners  if the Company  intends to
market,  sell and  distribute  such  product(s) in the  Territory.  In addition,
except for  relationship  created by the  Agreement,  there is no other material
relationship between the Company or Chefaro Italia.

     The  foregoing  is qualified  in its  entirety by the  Agreement.  For more
information, see the Agreement attached as Exhibit 10.


Section 9 - Financial Statements and Exhibits

Item 9.01   Financial Statements and Exhibits

    Exhibit No.     Exhibit Description
    ----------      -------------------

       10           Agreement  between  Remedent  NV and Chefaro  Pharma  Italia
                    S.R.L. dated February 15, 2006




                                       2

<PAGE>

                                  Exhibit Index

    Exhibit No.     Description
    -----------     -----------

       10           Agreement  between  Remedent  NV and Chefano  Pharma  Italia
                    S.R.L. dated February 15, 2006



                                       3

<PAGE>

                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                            REMEDENT, INC.
                                            a Nevada Corporation


Dated:  February 22, 2006                   /s/ Robin List
        -------------------                 ------------------------------------
                                            Robin List, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8k.txt", "secsgml_size_bytes": 5119}]
{"company-data": {"conformed-name": "REMEDENT, INC.", "cik": "0001078037", "assigned-sic": "3843", "irs-number": "860837251", "state-of-incorporation": "NV", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-15975", "film-number": "06635839"}, "business-address": {"street1": "XAVIER DE COCKLAAN 42", "city": "DEURLE", "state": "C9", "zip": "9831", "phone": "011-32-9-321-7090"}, "mail-address": {"street1": "XAVIER DE COCKLAAN 42", "city": "DEURLE", "state": "C9", "zip": "9831"}, "former-company": [{"former-conformed-name": "REMEDENT USA INC", "date-changed": "20050609"}, {"former-conformed-name": "REMEDENT USA INC/AZ", "date-changed": "19991220"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 15, 2006

                                 REMEDENT, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)

           Nevada                         001-15975               86-0837251
           -------                        ---------               ----------
(State or other jurisdiction of    (Commission File Number)    (I.R.S. Employer
         incorporation                                       Identification No.)
       or organization)

                           Xavier de Cocklaan 42, 9831
                                 Deurle, Belgium
                                 ---------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                011-329-321-7080
                                ----------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

     On February 15, 2006,  Remedent NV, a wholly-owned  subsidiary of Remedent,
Inc. (the "Company") entered into an Agreement with Chefaro Pharma Italia S.R.L,
a corporation organized under the laws of Italy ("Chefaro Italia").  Pursuant to
the Agreement, commencing on March 1, 2006, Chefaro Italia will be the Company's
sole and exclusive  distributor of the iWhite(R) products ("Products") in Italy,
Vatican City, and Republic of San Marino  ("Territory").  The Agreement requires
Chefaro Italia to order minimum  quantities of the Products in accordance to the
terms of the  Agreement.  In the event  that  Chefaro  Italia  fails to sell the
minimum  quantities of the Products within any given year, the Company will have
a right to terminate the Agreement upon one (1) month prior written notice.

     The term of the  Agreement is for an initial  three (3) years (the "Initial
Term"), unless terminated by either party under the Agreement.  After the end of
the Initial Term,  the Agreement will  automatically  be extended for successive
two (2) year terms  ("Additional  Term")  unless the  Agreement is terminated by
written notice at least six (6) months before the expiration of the Initial Term
or the respective  Additional  Term. The Agreement grants Chefaro Italia a first
of first refusal to market,  sell and distribute other product(s) of the Company
on terms  mutually  agreeable  between the  partners  if the Company  intends to
market,  sell and  distribute  such  product(s) in the  Territory.  In addition,
except for  relationship  created by the  Agreement,  there is no other material
relationship between the Company or Chefaro Italia.

     The  foregoing  is qualified  in its  entirety by the  Agreement.  For more
information, see the Agreement attached as Exhibit 10.

Section 9 - Financial Statements and Exhibits

Item 9.01   Financial Statements and Exhibits

    Exhibit No.     Exhibit Description
    ----------      -------------------

       10           Agreement  between  Remedent  NV and Chefaro  Pharma  Italia
                    S.R.L. dated February 15, 2006

                                       2
Exhibit Index

    Exhibit No.     Description
    -----------     -----------

       10           Agreement  between  Remedent  NV and Chefano  Pharma  Italia
                    S.R.L. dated February 15, 2006

                                       3
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                            REMEDENT, INC.
                                            a Nevada Corporation

Dated:  February 22, 2006                   /s/ Robin List
        -------------------                 ------------------------------------
                                            Robin List, Chief Executive Officer